Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1998 Jun 1;101(11):2415-26.
doi: 10.1172/JCI2950.

Dilated cardiomyopathy in transgenic mice expressing a dominant-negative CREB transcription factor in the heart

Affiliations

Dilated cardiomyopathy in transgenic mice expressing a dominant-negative CREB transcription factor in the heart

R C Fentzke et al. J Clin Invest. .

Abstract

Idiopathic-dilated cardiomyopathy (IDC) is a common primary myocardial disease of unknown etiology characterized by progressive biventricular failure, cardiac dilatation, and premature mortality. Here we show that transgenic mice expressing a dominant-negative form of the CREB transcription factor (CREBA133) under the control of the cardiac myocyte-specific alpha-MHC promoter develop dilated cardiomyopathy that closely resembles many of the anatomical, physiological, and clinical features of human IDC. Between 2 and 20 wk of age, these mice develop four chamber cardiac dilatation, decreased systolic and diastolic left ventricular function, and attenuated contractile responses to the beta-adrenergic agonist, isoproterenol. Histologically, the CREBA133 hearts demonstrated both atrophic and hypertrophied fibers as well as significant interstitial fibrosis. These anatomical and hemodynamic changes were associated with hepatic congestion and peripheral edema, intracardiac thrombi, and premature mortality. Taken together, these results implicate CREB as an important regulator of cardiac myocyte function and provide a genetic model of dilated cardiomyopathy which should facilitate studies of both the pathogenesis and therapy of this clinically important disorder.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Lancet. 1993 Dec 11;342(8885):1441-6 - PubMed
    1. Cell. 1997 Feb 7;88(3):393-403 - PubMed
    1. Science. 1994 Apr 22;264(5158):582-6 - PubMed
    1. Circ Res. 1994 Jun;74(6):1042-9 - PubMed
    1. Cell. 1994 Jun 3;77(5):713-25 - PubMed

Publication types

Substances